알부민 시장 : 공급원, 유형, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Albumin Market was valued at USD 6.53 billion in 2023, expected to reach USD 6.94 billion in 2024, and is projected to grow at a CAGR of 6.61%, to USD 10.23 billion by 2030.

The scope and definition of the albumin market are rooted in its diverse applications in pharmaceuticals, diagnostics, and the food industry. Albumin, a protein derived from human plasma, is essential for maintaining oncotic pressure and transporting hormones, drugs, and other substances in the bloodstream. Its necessity is heightened in medical settings, particularly in treating hypoalbuminemia, surgical procedures, and managing liver diseases, as well as in the biotechnology industry for cell culture media formulations. The end-use scope extends to hospitals, research institutes, and diagnostic labs, where albumin's role is critical in therapeutic and research applications. Key growth influencers include the increasing prevalence of chronic diseases, a rise in surgical procedures, and advancements in biotechnology enhancing albumin production and formulation. Additionally, the burgeoning demand for albumin in the cosmetics and food industry as a stabilizing and emulsifying agent presents potential growth opportunities. Companies can capitalize on these opportunities by investing in research to develop albumin-based products with enhanced stability and effectiveness, such as improved drug delivery systems. However, the market faces limitations like stringent regulatory frameworks governing albumin use and production, and the high cost of therapies, which can be barriers to market growth. Moreover, ethical concerns over albumin sourced from human plasma pose challenges, pushing the demand for recombinant albumin solutions. In terms of innovation, emphasis should be placed on developing synthetic or plant-based albumin alternatives and advancing recombinant DNA technology to decrease reliance on human plasma sources. The nature of the albumin market is dynamic, driven by continual scientific advancements and increasing healthcare demands, positioning it for substantial growth but necessitating strategic navigation of regulatory and ethical challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Albumin Market

The Albumin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Incidence of chronic diseases and use of albumin as a predictor of postoperative surgical site infections
  • Surging utilization of albumin as a food and cosmetic ingredient
• Market Restraints
  • Potential of albumin to cause transmission of infections
• Market Opportunities
  • Ongoing research activities regarding albumin nanoparticles
  • Advancements in albumin production and purification methods
• Market Challenges
  • Stringent regulations associated with albumin manufacturing and quality control

Porter's Five Forces: A Strategic Tool for Navigating the Albumin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Albumin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Albumin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Albumin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Albumin Market

A detailed market share analysis in the Albumin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Albumin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Albumin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Albumin Market, highlighting leading vendors and their innovative profiles. These include Rockland Immunochemicals Inc., VitroScient, Serion GmbH, Kraeber & Co. GmbH, Promega Corporation, Rocky Mountain Biologicals, LLC, CENTURION PHARMA Ilac Sanayi ve Ticaret A.S., Glentham Life Sciences Limited, GC Biopharma Corp., Octapharma AG, F. Hoffmann-La Roche AG, Bio Products Laboratory Ltd., LGC Science Group Holdings Limited, Bio-Rad Laboratories, Inc., Biorbyt Ltd., Kedrion S.p.A, Lazuline Biotech Private Limited, Boston BioProducts Inc., Bristol-Myers Squibb Company, Merck KGaA, Agilent Technologies, Inc., Dem Ilac, Biogenix Inc. Pvt. Ltd., Biowest SAS, SK Plasma, CSL Limited, Midas Pharma GmbH, China Biologic Products Holdings, Inc. by Taibang Biologic Group, Aadi Bioscience, Inc., Avantor Inc., Thermo Fisher Scientific Inc., Prospec-Tany Technogene Ltd., Bio-Techne Corporation, Becton, Dickinson and Company, Atlantis Bioscience Pte Ltd., Baxter International Inc., Akron Biotech, InVitria, Biophyll GmbH, Takeda Pharmaceuticals Company Limited, Sartorius AG, Grifols SA, Ventria Bioscience Inc., and InVitroCare Inc..

Market Segmentation & Coverage

This research report categorizes the Albumin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Source, market is studied across Animal Sources and Plant Sources. The Animal Sources is further studied across Bovine Serum Albumin, Human Serum Albumin, and Ovalbumin.
• Based on Type, market is studied across Non-Recombinant and Recombinant.
• Based on Application, market is studied across Cosmetic Ingredient, Culture Media, Drug Delivery, Food Ingredient, Therapeutic, and Vaccine Ingredient.
• Based on End User, market is studied across Pharmaceutical & Biotechnology and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Incidence of chronic diseases and use of albumin as a predictor of postoperative surgical site infections
    • 5.1.1.2. Surging utilization of albumin as a food and cosmetic ingredient
  • 5.1.2. Restraints
    • 5.1.2.1. Potential of albumin to cause transmission of infections
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research activities regarding albumin nanoparticles
    • 5.1.3.2. Advancements in albumin production and purification methods
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations associated with albumin manufacturing and quality control
• 5.2. Market Segmentation Analysis
  • 5.2.1. Source: Consumer shift toward the plant-based albumins due to enhanced sustainability for specific therapeutic purposes.
  • 5.2.2. Type: Enhanced emphasis on the research and development of recombinant albumin as a synthetic protein to promote recombinant DNA technology
  • 5.2.3. Application: Rising focus on vaccine manufacturing and drug delivery applications
  • 5.2.4. End-User: Extensive end-users of the albumin in hospitals and blood banks
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Albumin Market, by Source

• 6.1. Introduction
• 6.2. Animal Sources
  • 6.2.1. Bovine Serum Albumin
  • 6.2.2. Human Serum Albumin
  • 6.2.3. Ovalbumin
• 6.3. Plant Sources

7. Albumin Market, by Type

• 7.1. Introduction
• 7.2. Non-Recombinant
• 7.3. Recombinant

8. Albumin Market, by Application

• 8.1. Introduction
• 8.2. Cosmetic Ingredient
• 8.3. Culture Media
• 8.4. Drug Delivery
• 8.5. Food Ingredient
• 8.6. Therapeutic
• 8.7. Vaccine Ingredient

9. Albumin Market, by End User

• 9.1. Introduction
• 9.2. Pharmaceutical & Biotechnology
• 9.3. Research Institutes

10. Americas Albumin Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Albumin Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Albumin Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Grifols Completes Enrollment In Phase 3 Study Of Long-Term Albutein (Albumin-Human Injection) Therapy For Patients With Decompensated Cirrhosis
  • 13.3.2. Kedrion's Global Portfolio Expands To China To Supply Human Albumin
  • 13.3.3. GC Biopharma inks USD 90mn deal for blood products in Brazil
  • 13.3.4. Albumedix Enters into Collaboration Agreement with Cell and Gene Therapy Catapult
  • 13.3.5. Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine
  • 13.3.6. American Regent Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)
  • 13.3.7. SK Plasma to build USD 250m blood products plant in Indonesia
  • 13.3.8. Grifols Inaugurates New Albumin Plant At its Expanding Dublin Site
  • 13.3.9. Sartorius acquires Albumedix: A player in advanced therapies based on recombinant albumin
  • 13.3.10. Taibang Biologic Group Secures Equity Raising of USD 300 Million

Companies Mentioned

• 1. Rockland Immunochemicals Inc.
• 2. VitroScient
• 3. Serion GmbH
• 4. Kraeber & Co. GmbH
• 5. Promega Corporation
• 6. Rocky Mountain Biologicals, LLC
• 7. CENTURION PHARMA Ilac Sanayi ve Ticaret A.S.
• 8. Glentham Life Sciences Limited
• 9. GC Biopharma Corp.
• 10. Octapharma AG
• 11. F. Hoffmann-La Roche AG
• 12. Bio Products Laboratory Ltd.
• 13. LGC Science Group Holdings Limited
• 14. Bio-Rad Laboratories, Inc.
• 15. Biorbyt Ltd.
• 16. Kedrion S.p.A
• 17. Lazuline Biotech Private Limited
• 18. Boston BioProducts Inc.
• 19. Bristol-Myers Squibb Company
• 20. Merck KGaA
• 21. Agilent Technologies, Inc.
• 22. Dem Ilac
• 23. Biogenix Inc. Pvt. Ltd.
• 24. Biowest SAS
• 25. SK Plasma
• 26. CSL Limited
• 27. Midas Pharma GmbH
• 28. China Biologic Products Holdings, Inc. by Taibang Biologic Group
• 29. Aadi Bioscience, Inc.
• 30. Avantor Inc.
• 31. Thermo Fisher Scientific Inc.
• 32. Prospec-Tany Technogene Ltd.
• 33. Bio-Techne Corporation
• 34. Becton, Dickinson and Company
• 35. Atlantis Bioscience Pte Ltd.
• 36. Baxter International Inc.
• 37. Akron Biotech
• 38. InVitria
• 39. Biophyll GmbH
• 40. Takeda Pharmaceuticals Company Limited
• 41. Sartorius AG
• 42. Grifols SA
• 43. Ventria Bioscience Inc.
• 44. InVitroCare Inc.